KR20230129467A - 항-푸코실-gm1 항체를 사용하는 조합 요법 - Google Patents

항-푸코실-gm1 항체를 사용하는 조합 요법 Download PDF

Info

Publication number
KR20230129467A
KR20230129467A KR1020237026366A KR20237026366A KR20230129467A KR 20230129467 A KR20230129467 A KR 20230129467A KR 1020237026366 A KR1020237026366 A KR 1020237026366A KR 20237026366 A KR20237026366 A KR 20237026366A KR 20230129467 A KR20230129467 A KR 20230129467A
Authority
KR
South Korea
Prior art keywords
antibody
seq
sequence
fucosyl
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237026366A
Other languages
English (en)
Korean (ko)
Inventor
위 류
사라 타넨바움-드비르
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20230129467A publication Critical patent/KR20230129467A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237026366A 2021-01-08 2022-01-07 항-푸코실-gm1 항체를 사용하는 조합 요법 Pending KR20230129467A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135479P 2021-01-08 2021-01-08
US63/135,479 2021-01-08
PCT/US2022/011564 WO2022150557A1 (en) 2021-01-08 2022-01-07 Combination therapy using an anti-fucosyl-gm1 antibody

Publications (1)

Publication Number Publication Date
KR20230129467A true KR20230129467A (ko) 2023-09-08

Family

ID=80119207

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237026366A Pending KR20230129467A (ko) 2021-01-08 2022-01-07 항-푸코실-gm1 항체를 사용하는 조합 요법

Country Status (10)

Country Link
US (1) US20240050564A1 (enExample)
EP (1) EP4274850A1 (enExample)
JP (1) JP2024503379A (enExample)
KR (1) KR20230129467A (enExample)
CN (1) CN116745322A (enExample)
AU (1) AU2022205648A1 (enExample)
CA (1) CA3204392A1 (enExample)
IL (1) IL304200A (enExample)
MX (1) MX2023007780A (enExample)
WO (1) WO2022150557A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201912657D0 (en) * 2019-09-03 2019-10-16 Scancell Ltd Binding members

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US8383118B2 (en) 2005-12-08 2013-02-26 Medarex, Inc. Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US11104739B2 (en) * 2016-04-14 2021-08-31 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
CN109475634A (zh) * 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
RU2765997C2 (ru) * 2017-03-30 2022-02-07 Мерк Патент Гмбх Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
MY205645A (en) * 2018-06-23 2024-11-02 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor

Also Published As

Publication number Publication date
IL304200A (en) 2023-09-01
WO2022150557A1 (en) 2022-07-14
EP4274850A1 (en) 2023-11-15
JP2024503379A (ja) 2024-01-25
CA3204392A1 (en) 2022-07-14
MX2023007780A (es) 2023-07-10
AU2022205648A9 (en) 2024-09-19
US20240050564A1 (en) 2024-02-15
CN116745322A (zh) 2023-09-12
AU2022205648A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
TWI733664B (zh) 包含抗ｐｄ１抗體及另一種抗體之組合的組合物
CN106999594B (zh) 用于治疗瘤形成的治疗组合
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
US20250361313A1 (en) Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
SG10202111905PA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
Baldo Monoclonal antibodies approved for cancer therapy
KR20230047498A (ko) 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
KR20170007750A (ko) Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제
US20240279342A1 (en) Compositions and methods for immunotherapy
WO2020007368A1 (zh) 低adcc/cdc功能性单抗及其制备方法与应用
CN111973739B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
US20240050564A1 (en) Combination therapy using an anti-fucosyl-gm1 antibody
KR20230069957A (ko) 암을 갖는 환자의 치료를 위한 pd-1 길항제 및 lag3 길항제 및 렌바티닙 또는 이의 약학적으로 허용가능한 염의 병용 요법
WO2023001118A1 (zh) 抗ox40抗体在联合用药中的应用
AU2007299582B2 (en) Anti-cancer antibodies against Lewisy and Lewisb antigens
EA049752B1 (ru) Комбинированная терапия с применением анти-фукозил-gm1 антитела
WO2025036445A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
WO2020049534A1 (en) Sting agonist and combination therapy thereof for the treatment of cancer
CN113365659A (zh) 抗pd-l1抗体治疗头颈癌的用途
WO2020063433A1 (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
KR20260054704A (ko) 항-pd-1 및 화학요법을 이용한 폐암 치료
JP2025519552A (ja) がんの治療のためのｓｉｒｐアルファ融合タンパク質及び抗ｃｄ１９抗体を含む併用療法
TW202523693A (zh) 手術前後基於抗ｐｄ－１之治療
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230802

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250107

Comment text: Request for Examination of Application